Rakshit Drugs Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
- Paid Up Capital ₹ 2.24 Cr
- Company Age 24 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 78.29 Cr
- Satisfied Charges ₹ 20.29 Cr
- Revenue Growth 11.61%
- Profit Growth -72.40%
- Ebitda -20.99%
- Net Worth 2.20%
- Total Assets -9.88%
About Rakshit Drugs
Rakshit Drugs Private Limited (RDPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 24 March 2000 and has a history of 24 years and 11 months. Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 2.24 Cr.
The company currently has active open charges totaling ₹78.29 Cr. The company has closed loans amounting to ₹20.29 Cr, as per Ministry of Corporate Affairs (MCA) records.
Anjaneya Chandana, Aruna Chandana, Avinash Chandana, and Two other members serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24230TG2000PTC034018
- Company No.
034018
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Mar 2000
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
What products or services does Rakshit Drugs Private Limited offer?
Rakshit Drugs Private Limited offers a wide range of products and services, including Pharma Ingredients & Raw Materials, Digestive System API, Anti Infective Drugs & Medicines, Antiviral Drugs, API (Active Pharmaceutical Ingredients), Cardiovascular Drugs & Medication, Immunosuppressive Drugs, Digestive System Drugs & Medicines, Laxatives, Common Disease Medicines.
Who are the key members and board of directors at Rakshit Drugs?
Executive Team (2)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Anjaneya Chandana ![]() | Managing Director | 24-Mar-2000 | Current |
Rajeshkumar Joshi ![]() | Managing Director | 07-May-2009 | Current |
Board Members (3)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Aruna Chandana ![]() | Whole-Time Director | 24-Mar-2000 | Current |
Avinash Chandana ![]() | Director | 25-Feb-2007 | Current |
Palem Srinivas ![]() | Director | 07-Jul-2008 | Current |
Financial Performance of Rakshit Drugs.
Rakshit Drugs Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 11.61% increase. The company also saw a substantial fall in profitability, with a 72.4% decrease in profit. The company's net worth moved up by a moderate rise of 2.2%.


- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Rakshit Drugs?
In 2023, Rakshit Drugs had a promoter holding of 100.00%. The company had 1 Subsidiary and 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Charges (Loans)
₹78.29 Cr
₹20.29 Cr
Charges Breakdown by Lending Institutions
- Others : 78.29 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
01 Feb 2008 | Others | ₹78.29 Cr | Open |
28 Mar 2017 | Sidbi | ₹9.00 M | Satisfied |
12 Jun 2009 | Amneal Pharmaceuticals Company (India) Private Limited | ₹13.00 Cr | Satisfied |
24 Jul 2008 | Hdfc Bank Limited | ₹0.88 M | Satisfied |
26 Apr 2002 | Lakshmi Vilas Bank Limited | ₹6.04 Cr | Satisfied |
How Many Employees Work at Rakshit Drugs?
Rakshit Drugs has a workforce of 34 employees as of Oct 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Deals i

Gain comprehensive insights into the Deals and Valuation data of Rakshit Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rakshit Drugs's trajectory.
Rating

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.